Posters
Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
October 24, 2026 | 10:00 AM - 12:00 PM
Location: Exhibit Hall A, Convention Center
Session Description
Poster Session
Posters
Rapid Progression in IgAN Despite Treatment: Real-World Evidence of Suboptimal Disease Control in the United States
Targeted-Release Budesonide Combined with Telitacicept in IgAN: A Preliminary Real-World Study
Efficacy and Safety of Long-Term Telitacicept Treatment in Patients with Primary IgAN: A Report of 25 Cases
Efficacy and Safety of Finerenone in Adults with IgAN: A 12-Month Real-World Study
Efficacy of Antiplatelet Therapy for IgAN in Nationwide Multicenter Prospective Cohort Study in Japan (JIGACS)
Limited Diagnostic Utility of Light Chain and IgA Subclass Staining in IgA-Type Monoclonal Gammopathy of Renal Significance
Real-World Efficacy of Nefecon in Patients with IgAN and an Exploratory Comparison with Telitacicept
Effect of the SGLT2 Inhibitor Dapagliflozin on Kidney Hemodynamics in Patients with IgAN
Hospitalizations for Cardiovascular Disease Among Middle-Aged and Older Adults with Lupus Nephritis and IgAN
Targeted-Release Budesonide (Nefecon) in Patients with Primary IgAN and Proteinuria 0.5-1.0 g/day: Real-World Efficacy and Safety
Design of a Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ARGX-121 in Adult Patients with Primary IgAN
Twelve-Month Continuous Nefecon in a Chinese Cohort with IgAN: Kinetics and Sustained Response
Characterization of Nutritional Intake by Disease Activity Status in IgAN
Efficacy and Safety of Nefecon in Chinese Patients with IgAN: Real-World Evidence
Efficacy and Safety of Targeted Complement Inhibitors in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis: A Systematic Review and Meta-Analysis
Emerging Targeted Therapies in IgAN: A Systematic Review Without Meta-Analysis (SWiM) of Phase 3 Randomized Controlled Trials
Online Continuing Medical Education Enhances Advanced Practice Provider Readiness for Emerging B-Cell-Modulating Therapies for IgAN
Online Continuing Medical Education Improves Clinical Insights into B-Cell-Targeted Therapies for IgAN Among Nephrologists
Efficacy of Sparsentan in FSGS: A Meta-Analysis of Randomized Clinical Trials
Targeted-Release Budesonide in IgAN: Real-World Efficacy and Safety in a Chinese Cohort
The IgAN Revolution and the Unmet Needs in Pediatric Patients
A Retrospective Study of IgAN from a Single Academic Center
Serum Gd-IgA1 and Gd-IgA1/C3 Ratio as Predictors of Pathological Features and Treatment Response to Nefecon in Patients with IgAN
Serum Galactose-Deficient IgA1 in IgAN: Cross-Sectional Comparison of Two Enzyme-Linked Immunosorbent Assays (ELISAs) Against Clinical and Histologic Severity in an Indian Cohort
Root Cause Analysis of Delayed IgAN Diagnosis: A Literature-Informed Equity and Implementation Science Framework
Atrasentan in Patients (Pts) with IgAN from East (E) Asia: Phase 3 ALIGN Final Data
Practice Variability and Individualized Treatment Selection in IgAN in the Era of Emerging Therapies
Comparative Efficacy of Nefecon vs. Telitacicept in IgAN: A Six-Month Retrospective Cohort Study
Medicare Prescription Drug Coverage of Medications for IgAN
MOSAIC-IgAN: Multi-Omics- and Artificial Intelligence (AI)-Based Subphenotyping of IgAN Among Diverse Populations
COMBO-IGNITE: Real-World Effectiveness and Early Safety Signals of Combination Therapy for IgAN
Neighborhood Deprivation and One-Year Kidney Outcomes in Patients with IgAN
Real-World Reasons for Discontinuation of Targeted-Release Budesonide in IgAN
Real-World Characteristics of Patients with IgAN Receiving Combination Therapy: A Retrospective Claims Analysis
Early Real-World Outcomes Among US Patients (Pts) with IgAN Receiving Atrasentan: APPRISE-IgAN Data Platform
Efficacy and Safety of Nefecon on Prevention of Relapse of IgAN (NEFRIN): Study Design of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Real-World Adherence to Oral Therapies in IgA Nephropathy
Association of Mesangial Hypercellularity, Endocapillary Hypercellularity, Segmental Sclerosis, Tubular Atrophy, and Crescent Formation (MEST-C)-Based Steroid Response Scores with Kidney Prognosis in Patients with IgAN at the National Kidney and Transplant Institute (NKTI): A Retrospective Cohort Study from January 2018 to December 2023
Evolving IgAN Landscape: Persistent Unmet Need Despite Expanding Therapeutic Options
Evaluation of KM55 Staining in IgAN as a Predictor of Progression to ESKD
Remission Trajectories of Targeted-Release Budesonide Across Mesangial Hypercellularity, Endocapillary Hypercellularity, Segmental Sclerosis, Tubular Atrophy, and Crescent Formation (MEST-C) Phenotypes in IgAN
Epidemiology and Prognostic Determinants of IgAN in Apulia, Southern Italy
Systemic Corticosteroids Combined with Targeted-Release Budesonide in Primary IgAN: A Single-Center Real-World Study
SGLT2 Inhibitors Among Middle-Aged and Older Adults with IgAN At-Risk of Progressive CKD and Cardiovascular Disease
Adverse Clinical Outcomes and Economic Burden of Corticosteroid Use in IgAN: A US Real-World Study
Preliminary Results of the Effect of SGLT2 Inhibitors on Renal Parameters of Patients with IgAN
Composite Kidney Failure End Points in Contemporary Phase 3 Randomized Controlled Trials of Novel Therapies for IgAN: A Systematic Review and Meta-Analysis Stratified by Mechanism of Action
Long-Term Managed Access Program (MAP) Data Confirm Sustained eGFR Stabilization with Iptacopan up to 24 Months in C3 Glomerulopathy (C3G)
Efficacy and Safety of Targeted Complement Inhibitors in Patients with C3 Glomerulopathy: A Systematic Review and Quantitative Synthesis of Randomized Controlled Trials
Real-World Kidney Outcomes Among C5 Inhibitor-Naive Patients Treated with First-Line Ravulizumab Therapy for Atypical Hemolytic Uremic Syndrome (aHUS)
User Experience with Pegcetacoplan On-Body Injector in Patients with C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis
Comparative Effectiveness of Complement-Targeted Therapies for C3 Glomerulopathy: A Systematic Review and Bayesian Network Meta-Analysis
Pharmacokinetic (PK), Pharmacodynamic (PD), and Exposure-Response (E-R) Analysis of Pegcetacoplan in C3 Glomerulopathy (C3G) and Primary Immune-Complex Membranoproliferative Glomerulonephritis (pIC-MPGN)
Targeting the Gut-Kidney Axis: Mediation Analysis of Immunological Biomarkers and Kidney Function Benefit with Nefecon in IgAN
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARGX-121 in Healthy Adult Participants: Results from the Phase 1 First-in-Human Study
Patterns of Kidney Involvement in the Phase 3 MITIGATE Trial of Inebilizumab in IgG4-Related Disease (IgG4-RD)
Association of Aspirin Use with Bleeding Complications After Native Kidney Biopsy
Effect of Intravenous (IV) Desmopressin on Bleeding After Kidney Biopsy: A Seven-Year Cohort Study
Timing of Anticoagulation Resumption and Risk of Delayed Hematoma After Kidney Biopsy: A Single-Center Cohort Study
Determinants of eGFR Decline in Sickle Cell Disease: A Systematic Review of Albuminuria (Alb) and Longitudinal Risk Factors